Impact of IFNγ in B16 melanoma metastasis.

Slides:

Advertisements

Similar presentations

Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.

Advertisements

Melanoma donor (MD) NK cells are functionally impaired/exhausted.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

IL-6 is dispensable for the suppressive activity of MDSC on primary CD4+ T-cell activation. IL-6 is dispensable for the suppressive activity of MDSC on.

Cetuximab treatment increases IFNγ receptor 1 expression.

ALT-803 administration increases peripheral blood cell counts of lymphocyte subsets in cynomolgus monkeys. ALT-803 administration increases peripheral.

Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in xenografted mice. Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in.

Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Definition of the cellular source of IL-22.

Adoptive transfer of purified activated G9Cα−/−

Exosome-mediated inhibition of T cells is reversible.

Protection from 4T1 tumor rechallenge in treated mice.

Ado loss drives TNF-dependent immune evasion.

Functional analysis of CAR-redirected primary NK cells.

M-MDSC:mast cell cross-talk in the regulation of TNFα production.

Antitumor immunity caused by DS-8201a.

Reduced tumor growth in CCR5-deficient mice is associated with perturbed killing ability of Treg cells. Reduced tumor growth in CCR5-deficient mice is.

CD49b+ cells from tumor-bearing mice are more prone to conversion into MDSCs compared with naive CD49b+ cells. CD49b+ cells from tumor-bearing mice are.

The presence of soluble IL12p70 during moDCpoly stimulation of KIRnegNKG2Aneg cells results in a dominant population of multifunctional NKG2Apos NK cells.

SDF-1/CXCR4 axis is involved in CD133+ tumor cell metastasis toward a lymphatic metastasis niche. SDF-1/CXCR4 axis is involved in CD133+ tumor cell metastasis.

The selective depletion of DTR-expressing FAP+/CD45+ and FAP+/CD45− tumoral cells from bone marrow chimeric mice by the administration of DTX. A, sketch.

Immune signatures of patients with short-, medium-, and long-term survival. Immune signatures of patients with short-, medium-, and long-term survival.

Β-Cryptoxanthin at a concentration of 10 μmol/L decreases proliferation in HCT116 cells after 6 and 8 days of treatment. β-Cryptoxanthin at a concentration.

Primary B16F10 tumor inhibits experimental metastasis formation in the lung. Primary B16F10 tumor inhibits experimental metastasis formation in the lung.

Experimental metastasis inhibition by primary tumors is mediated by NK cells and IFNγ. Experimental metastasis inhibition by primary tumors is mediated.

PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.

Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.

IDO deficiency delays the development of pulmonary metastases.

Induction of a tumor-specific immune response following radiofrequency ablation (RFA). Induction of a tumor-specific immune response following radiofrequency.

GPR55 regulates γδT cell egress from PP and homing of gut-tropic CD8 T cells to the small intestine. GPR55 regulates γδT cell egress from PP and homing.

Increase in proliferation and activation of immune cells in peripheral blood after NKTR-214 treatment. Increase in proliferation and activation of immune.

ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells, and NK cells. ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells,

Irradiated whole-cell vaccination with MOC1, but not MOC2, induces immunologic memory. Irradiated whole-cell vaccination with MOC1, but not MOC2, induces.

Canonical but not adaptive NK-cell function is suppressed by Tregs.

M-CSFR inhibition decreases tumor-associated macrophages in mesothelioma and improves the DC therapy induced CD8+ T-cell phenotype. M-CSFR inhibition decreases.

Northern blot analysis of maspin in cancer cell lines and human tissues. Northern blot analysis of maspin in cancer cell lines and human tissues. A, HMECs.

Influenza vaccine enhances NK cell function through IFN-α.

DAC treatment alters immune cell composition and enhances cytokine production in the peritoneal lavage. DAC treatment alters immune cell composition and.

The CD8+ cytotoxic T-cell response in Ron TK−/− hosts in response to tumors is necessary and sufficient to block metastasis. The CD8+ cytotoxic T-cell.

A and B, intratumoral DC-AdCCL21 leads to reduction in growth rates of bilateral tumors. A and B, intratumoral DC-AdCCL21 leads to reduction in growth.

MDSC-derived IL-6 enhances tumor progression through the inhibition of tumor-specific TH1 development and of their helper activity for CD8+ T cells. MDSC-derived.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

CPI-444 enhances T-cell activation in MC38 tumors.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Immunotherapy of NK-92-S3KD increases anticancer effector productions in HepG2-bearing mice. Immunotherapy of NK-92-S3KD increases anticancer effector.

SPARC is required for spontaneous metastasis

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

Inhibition of CD20 mRNA expression by ibrutinib correlates with reduced NF-κB activity. Inhibition of CD20 mRNA expression by ibrutinib correlates with.

TGFβ1/Smad3 signaling suppresses IFNγ production via an E4BP4-dependent mechanism in NK-92 cells. TGFβ1/Smad3 signaling suppresses IFNγ production via.

T cells with a ROR1-specific CAR eliminate tumor cells in vivo only with a modified long spacer. T cells with a ROR1-specific CAR eliminate tumor cells.

Serum IFNγ and immune responses following tecemotide/cisplatin combination treatment in a urethane-induced hMUC1.Tg lung cancer mouse model. Serum IFNγ.

LSECtin, expressed by B16 cells, inhibits the tumor-specific immune responses both in vivo and in vitro. LSECtin, expressed by B16 cells, inhibits the.

Antibody-mediated blockade of the immune-inhibitory PD-1–PD-L1 signaling pathway prolongs survival in poly(I:C)-treated mice. Antibody-mediated blockade.

Nanostring analysis of tumors after ILI and after combination limb infusion and ipilimumab. Nanostring analysis of tumors after ILI and after combination.

IL35 regulation of tumor growth is accompanied by suppression of CD4+ effector T-cell activity and expansion of Tregs. IL35 regulation of tumor growth.

Increased tumorigenic activities of TIM-3–expressing RCC cells.

Transgenic mice with constitutively active NIK show increased tumor growth in bone. Transgenic mice with constitutively active NIK show increased tumor.

BV6 increases bone metastasis.

Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3 therapy. Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3.

The effect of βAR signaling on the generation of a cytotoxic CD8+ T-cell response in vivo. The effect of βAR signaling on the generation of a cytotoxic.

Activation status of NK cells is associated with therapeutic effects of TKIs. PBMCs from CML patients were cocultured with HLA class I–deficient K562 cells.

Effect of HDC on the ROS production in mouse lungs after melanoma cell inoculation. Effect of HDC on the ROS production in mouse lungs after melanoma cell.

MDSC population in patient peripheral blood.

Bezafibrate increases the number of effector CTLs by enhancing their survival capacity and proliferation. Bezafibrate increases the number of effector.

Silencing E4BP4 abrogates the promoting effect of SMAD3 knockdown on IFNγ production in NK-92 cells. Silencing E4BP4 abrogates the promoting effect of.

RIL21 and checkpoint blockade restore IFNγ production in Tim-3+PD-1+ intratumoral NK cells from cancer patients. rIL21 and checkpoint blockade restore.

Waterfall plots in 82 ipilimumab-refractory patients receiving nivolumab (3 mg/kg) with (n = 14) or without (n = 82) a peptide vaccine. Waterfall plots.

Presentation transcript:

Impact of IFNγ in B16 melanoma metastasis. Impact of IFNγ in B16 melanoma metastasis. A, Box plots of B16F10 metastasis at 3 weeks after i.v. inoculation of 50,000, 100,000, or 150,000 B16 melanoma cells into WT and Ifng−/− mice (n = 6 for each group, t test; two independent experiments). B, Left, the lack of efficacy of systemic treatment with HDC on metastasis formation at 3 weeks after inoculation of B16 melanoma cells into Ifng−/− mice (n = 19–21, t test; four independent experiments). B, Right, effects of systemic treatment with HDC on metastasis formation (% of control) in Ifng−/− mice that received the adoptive transfer of purified NK cells from WT mice (n = 9 for each group, t test) or purified NK cells from Ifng−/− mice (n = 6, t test; two independent experiments). C, The presence of WT Ifng in peripheral blood collected from six representative Ifng−/− mice who had received adoptive transfer of WT NK cells (lanes 1–3) or Ifng−/− NK cells (lanes 4–6) 2 days earlier. PCR was performed for WT Ifng and the disrupted IFNγ gene of Ifng−/− mice. Nonsignificant values: n.s., P > 0.05; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. Ebru Aydin et al. Cancer Immunol Res 2017;5:804-811 ©2017 by American Association for Cancer Research